Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilson H Miller

Showing results (141-150 of 168) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2013
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancerJohn P Crown, Véronique Diéras, Elzbieta Staroslawska, et al.
Journal for Immunotherapy of Cancer|November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapyToni K Choueiri, Harriet Kluger, Saby George, et al.
The New England Journal of Medicine|June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanomaCaroline Robert, Luc Thomas, Igor Bondarenko, et al.
Science Advances|September 13, 2024
Blocking tumor-intrinsic MNK1 kinase restricts metabolic adaptation and diminishes liver metastasisSamuel E J Preston, Michael S Dahabieh, Raúl Ernesto Flores González, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2019
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.
Nature Medicine|April 24, 2019
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trialJordi Rodon, Jean-Charles Soria, Raanan Berger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled AnalysisSandra P D'Angelo, James Larkin, Jeffrey A Sosman, et al.
Cancer|January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaWalter M Stadler, Robert A Figlin, David F McDermott, et al.
Pageof 17

Showing results (141-150 of 168) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2013
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancerJohn P Crown, Véronique Diéras, Elzbieta Staroslawska, et al.
Journal for Immunotherapy of Cancer|November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapyToni K Choueiri, Harriet Kluger, Saby George, et al.
The New England Journal of Medicine|June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanomaCaroline Robert, Luc Thomas, Igor Bondarenko, et al.
Science Advances|September 13, 2024
Blocking tumor-intrinsic MNK1 kinase restricts metabolic adaptation and diminishes liver metastasisSamuel E J Preston, Michael S Dahabieh, Raúl Ernesto Flores González, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2019
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.
Nature Medicine|April 24, 2019
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trialJordi Rodon, Jean-Charles Soria, Raanan Berger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled AnalysisSandra P D'Angelo, James Larkin, Jeffrey A Sosman, et al.
Cancer|January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaWalter M Stadler, Robert A Figlin, David F McDermott, et al.
Pageof 17